VC firm
Abingworth
Also known as Abingworth Bioventures, Abingworth Bioventures 8 LP, Abingworth Bioventures VI LP, Abingworth Bioventures VII LP, Abingworth Clinical Co Development, Abingworth Clinical Co-Development Fund 2 LP, Abingworth Clinical Co-Development Fund LP
- Investor type
- VC
- Investing status
- Activeas of 2026-09-17Source (opens in a new tab)
- Headquarters
- LONDON, United Kingdom
- Latest fund size
- $207MSEC amount sold, as of 2020-11-19Source (opens in a new tab)
- Funds
- 5
- Check size
- $15-$30m In total per companySource (opens in a new tab)
- Legal name
- Abingworth LLP
Claim, correct or request removal
Record updated 30 September 2026
About
Since our first biotech investment nearly forty years ago, Abingworth has helped young biopharma companies on both sides of the Atlantic turn the latest scientific discoveries into dozens of new treatments for patients.
Investment approach
- Thesis
- Our portfolio is driven by patients in need, and opportunities to develop and commercialise important new treatment options for them.Source (opens in a new tab)
- Investing status notes
- All are actively investing.
Funds
- Abingworth Clinical Co-Development Fund 2 LP
- $207MVintage 2020, Main fund, SEC amount sold
- Abingworth Bioventures 8 LP
- $132MVintage 2019, Main fund, SEC amount sold
- Abingworth Bioventures VII LP
- $240MVintage 2016, Main fund, SEC amount sold
- Abingworth Clinical Co-Development Fund LP
- Vintage 2015Main fund
- Abingworth Bioventures VI LP
- $206MVintage 2012, Main fund, SEC amount sold
SEC registration
- SEC CIK
- 1552388, 1658235, 1688313
Locations
- Office
- London, United Kingdom
- Office
- Menlo Park, CA, United States
- Office
- New York, NY, United States
Loading relationship preview